April 22nd - 25th


Psychedelic compounds have a rich and fascinating history of use in spiritual and healthcare settings. After a nearly 60-year hiatus, recent advances in clinical research indicate that these medicines may soon be available to the public as treatments for some of humanity’s most profound forms of suffering: alcoholism, drug addiction, PTSD, and depression. Psychotherapists and other healthcare providers are increasingly called upon to help clients integrate profoundly meaningful psychedelic experiences into the fabric of their daily lives, resulting in long-term positive changes.

This 3-day retreat is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes experiential learning, demonstrations, self-reflection, and role-play exercises. The themes of spirituality, ethics, and critical discussion will be woven throughout the program with opportunities for connection, collaboration, and building community.

We start with the premise that your patients are curious about psychedelic research, and so are you! The early part of our program gives some background on psychedelic compounds, their history, and current research with MDMA and Psilocybin-assisted therapy. We then discuss recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment. We then move to the practicalities of defining integration and how it can occur in a clinical setting. We focus on translating research findings into clinical practice, including working with patients who are considering using psychedelics, actually using psychedelics, or have used them in the past. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues. Program participant clinicians will complete the retreat with a conceptual and practical understanding of how to engage clients in discussions about psychedelics that are balanced, reduce potential for harm, and increase the potential for benefit from these experiences.

Learning Objectives:

  • Discuss the historical justifications for psychedelic clinical research
  • Describe key theoretical approaches to psychedelic-assisted therapy
  • Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients
  • Compare psychedelic integration psychotherapy to integration in peer and shamanic settings
  • Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
  • Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use
  • List contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
  • Describe the role of the therapist in an individual's integration psychotherapy process


Choose a Pricing Option

$525

Full Access to 4-Day Workshop

$590

Full Access to 4-Day Workshop - Continuing Education Fee Included

$795

Full Access to 4-Day Workshop - Continuing Medical Education Fee Included

Information on Continuing Education Credit for Health Professionals

• CE credits for psychologists are provided by the Spiritual Competency Resource Center (SCRC) which is co-sponsoring this program. The Spiritual Competency Resource Center is approved by the American Psychological Association to sponsor continuing education for psychologists. The Spiritual Competency Resource Center maintains responsibility for this program and its content.

• The California Board of Behavioral Sciences accepts CE credits for LCSW, LPCC, LEP, and LMFT license renewal for programs offered by approved sponsors of CE by the American Psychological Association.

• LCSWs, MFTs, and other mental health professionals from states other than California need to check with their state licensing board as to whether or not they accept programs offered by approved sponsors of CE by the American Psychological Association.

• SCRC is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California.

• For questions about receiving your Certificate of Attendance, contact Michael Burbank at [email protected] For questions about CE credits, visit www.spiritualcompetency.com or contact David Lukoff, PhD at [email protected]

• The filing fee for CEs for this program is $65, payable to Menla either at registration or by the time you check in.



For Medical Professionals

Continuing Medical Education (CME)

In support of improving patient care, this activity has been planned and implemented by Cine-Med and Medical Resource Association. Cine-Med is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Ciné-Med designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Dr. Elizabeth Nielson


Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

Dr. Ingmar Gorman


Dr Ingmar Gorman is a co-founder of Fluence and a psychologist who specializes in assisting populations who have a relationship with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. Dr. Gorman is a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics. After completing his NIH postdoctoral fellowship at New York University, Dr. Gorman stepped down as director of the Psychedelic Education and Continuing Care Program to focus his efforts on Fluence and the training of future therapists.


Schedule


  Thursday, April 22nd - Day One
Available in days
days after you enroll
  Friday, April 23rd - Day Two
Available in days
days after you enroll
  Saturday, April 24th - Day Three
Available in days
days after you enroll
  Sunday, April 25th - Day Four
Available in days
days after you enroll